Since Nuplazid launched in June 2016, the FDA has received more than 700 reports of deaths linked to it. The FDA should pull this drug from the market.
The rest of the world has sunscreens with more advanced ingredients than in the US. Why are we behind in protecting against skin cancer?
Bayer will stop selling Essure, a permanent birth control device fraught with issues, by the end of the year. Much of the reason is because of patients reporting adverse events.
Complementary therapies should be just that: a complement, not a substitute, for proven treatments. Don’t rely on them alone.
Patients who need Rx opioids for chronic pain say it has been getting harder to obtain them. How do you fight opioid abuse without harming patients?
Many FDA advisory committee members later receive kickbacks from the very pharma companies whose drug they approved. How can we stem conflicts of interest?
While many drugs are being approved more rapidly, are they much of an improvement over existing medications? What are the implications of faster drug approvals for patients?
An FDA meeting early next month will focus on developing drugs for chronic pain and patient input on the topic will be emphasized. Find out how your voice can be heard in the drug development process.
The suicides of 2 high-profile individuals has renewed focus on mental illness the same week a CDC report found a drastic rise in suicide rates. Are we approaching, treating and funding mental health appropriately and what more can be done?
What can a country where sheep outnumber residents by about 2.5:1 teach the US about living more healthy? Plenty.
It’s time to face the reality that the epidemic of school shootings is as much a public health issue as it is a gun control issue. It will take a combination of approaches to end. And we must put politics aside.
A stroll around the exhibit area of the American Psychiatric Association Conference demonstrates how pharma marketing can influence the prescribing patterns of doctors — possibly at the expense of patients’ health.